ABL Bio is accelerating its global drug development by showcasing clinical results for two dual antibody immuno-oncology drugs at the European Society for Medical Oncology (ESMO 2026).
On Monady, ABL Bio revealed clinical data for Givastomig (ABL111) and Ragistomig (ABL503) at ESMO 2026.
Both candidates leverage the company’s proprietary 4-1BB-based dual antibody platform, Grabody-T, and are being jointly developed with U.S.-based Novabridge Biosciences.
Givastomig targets claudin 18.2, a protein expressed in stomach cancer and other malignancies. The latest Phase 1b trial analysis evaluated efficacy and safety in 71 patients.
Results showed an impressive 79% objective response rate (ORR) in the 8 mg/kg dosing group (23 out of 29 patients), with a disease control rate (DCR) of 97% (28 out of 29 patients). Patients with claudin 18.2 expression rates above 75% achieved an 82% ORR, while those in the 1-74% range saw a 75% ORR.
Notably, no grade 4-5 treatment-related adverse events were reported. Based on these promising efficacy and safety profiles, ABL Bio has selected 8 mg/kg as the dose for future clinical trials.
Ragistomig demonstrated objective response rates of 11.8% and 21.1% in the 3 mg/kg and 5 mg/kg dosing groups, respectively, when administered every six weeks. ABL Bio plans to focus future development on patients who have not responded to existing immune checkpoint inhibitors.
Dr. Lee Sang-hoon, Chief Executive Officer (CEO) of ABL Bio, stated that the long-term follow-up data for Givastomig has bolstered the confidence in its sustained efficacy and safety profile. It’s ramping up preparations for Phase 3 trials in partnership with Novabridge and aggressively pursuing combination therapies with PD-1 inhibitors for Ragistomig.
In a separate announcement on October 14, the company reported no dose-limiting toxicities in U.S. Phase 1 trials for two dual antibody drug conjugate (ADC) candidates.
Last year, ABL Bio inked major deals with pharmaceutical giants GSK and Eli Lilly, licensing its blood-brain barrier (BBB) shuttle platform Grabody-B.